Information Provided By:
Fly News Breaks for September 23, 2015
PCRX, HRTX
Sep 23, 2015 | 08:07 EDT
JMP Securities hiked its price target on Heron (HRTX) after the company announced positive data from the Phase 2 study of its pain control drug HTX-011 in the bunionectomy setting. The firm thinks that the data is "impressive," and it believes that the data indicates that the drug is superior to a competing offering from Pacira (PCRX). The firm keeps an Outperform rating on the shares.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX